Research and educational context only. This article reviews molecular identity, analytical-quality principles, published laboratory findings, animal studies, and limited human evidence concerning AOD9604.
It does not provide instructions for dosing, administration, reconstitution, compounding, self-experimentation, medical treatment, or veterinary use. AOD9604 is not an FDA-approved drug, and no statement below should be interpreted as evidence that a research-grade or compounded material is safe, effective, sterile, or suitable for administration.
AOD9604 is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH). It has been studied primarily in relation to adipose-tissue lipid mobilization, whole-body substrate oxidation, and metabolic adaptations involving the β3-adrenergic system.

The evidence base is uneven. Several older rodent studies reported reduced body-weight gain, increased lipolytic activity, or increased fat oxidation under defined experimental conditions.
A later human development program generated short-term safety and tolerability observations, but the largest obesity study did not demonstrate statistically significant weight-loss efficacy at its prespecified primary endpoint. A 2024 FDA review also identified major gaps in physicochemical characterization, route-specific safety, long-term safety, pharmacokinetics, immunogenicity assessment, and evidence of effectiveness.[2]
Many molecular events frequently discussed alongside AOD9604—including cyclic AMP accumulation, protein kinase A activation, hormone-sensitive lipase phosphorylation, perilipin remodeling, and mitochondrial fatty-acid oxidation—are established components of adipocyte biology. They should not be described as direct AOD9604 mechanisms unless the corresponding endpoint was measured in an AOD9604-specific experiment.
This review therefore separates:
- observations measured directly in AOD9604 studies;
- general adipocyte and mitochondrial biology used as an interpretive framework;
- mechanistic hypotheses that remain unresolved;
- human findings and their limitations;
- analytical and regulatory questions that cannot be answered by HPLC purity alone.
Molecular Identity and Chemical Form
AOD9604 is commonly described as a 16-amino-acid peptide formed from the hGH 177–191 sequence with an additional N-terminal tyrosine. Its sequence is:
YLRIVQCRSVEGSCGF
The two cysteine residues form an intramolecular disulfide bond between Cys7 and Cys14. The disulfide configuration is part of the molecular identity and can affect conformation, stability, aggregation behavior, and biological activity.[1][2]
Free Base and Acetate Are Distinct Bulk Drug Substances
AOD9604 free base and AOD9604 acetate share the same peptide active moiety, but they are not analytically interchangeable descriptions. FDA has treated them as distinct bulk drug substances because a free base and a salt can differ in formula, molecular weight, counterion content, solubility, stability, material behavior, and potentially pharmacokinetic or pharmacodynamic properties.[2]
| Material | Molecular formula | Average molecular weight | Interpretive point |
|---|---|---|---|
| AOD9604 free base | C78H123N23O23S2 | 1,815.09 g/mol | The PubChem and FDA values refer to the disulfide-bonded free-base peptide. |
| AOD9604 acetate | C80H127N23O25S2 | 1,875.1 g/mol | The additional mass reflects the acetate salt as represented in FDA’s evaluation. |
FDA identified public-domain and submitted-document inconsistencies in which an acetate material was accompanied by the free-base CAS number, molecular formula, or molecular weight. The agency also noted discrepancies among supplier descriptions of the sequence and chemical structure.[2]
Mass-spectrometric signals must therefore be interpreted carefully. Observed m/z, charge state, isotope envelope, adducts, deconvoluted neutral mass, theoretical monoisotopic mass, average molecular weight, and the mass of a salt or solvated material are different analytical concepts.
A peptide-related ion near the expected free-peptide mass does not, by itself, establish the counterion, salt stoichiometry, net peptide content, disulfide configuration, impurity profile, or biological suitability of the material.
Distinguishing Related Peptides
AOD9604 should be distinguished from full-length hGH, the unmodified hGH 177–191 fragment, commercial products loosely described as “hGH fragment 176–191,” and historical analogues such as AOD9401.
An earlier study of an unmodified synthetic hGH 177–191 sequence reported an antilipogenic effect in rat adipose tissue but did not find a statistically significant lipolytic effect by glycerol release under the conditions tested.[3]
AOD9401 was investigated separately in Zucker fatty rats and isolated adipose tissue. That study reported changes in hormone-sensitive lipase activity, acetyl-CoA carboxylase activity, diacylglycerol release, adipocyte size, and body-weight gain in its specific models.[4]
Results obtained with full-length hGH, unmodified hGH fragments, AOD9401, LAT8881, or other related sequences should not be assigned automatically to AOD9604. Sequence, disulfide configuration, chemical form, purity profile, formulation, and experimental identity must be confirmed.
What Direct AOD9604 Preclinical Studies Reported
Obese Zucker Rats
A published study evaluated AOD9604 in obese Zucker rats. Under the reported protocol, the investigators observed lower cumulative body-weight gain than in controls and increased lipolytic activity in adipose tissue isolated from AOD9604-exposed animals.
A euglycemic-clamp assessment did not show the adverse insulin-sensitivity effect associated with intact hGH in the compared conditions.[5]
These findings are limited to the tested rat strain, route, exposure schedule, controls, tissue preparation, and analytical methods. They do not establish a universal response across species, concentrations, formulations, or adipose depots.
Obese ob/ob Mice and hGH-Receptor Assays
A separate study examined AOD9604 in obese ob/ob mice and lean C57BL/6J mice. The investigators measured body-weight change, food intake, resting energy expenditure, substrate oxidation, plasma glucose, insulin, and plasma glycerol.
Under the reported conditions, AOD9604 reduced body-weight gain in obese mice and was associated with increased fat oxidation and increased plasma glycerol, which was used as an index of lipolysis.[6]
The same study used BaF-B03 cells engineered to express the human growth hormone receptor. In that assay, AOD9604 did not compete with radiolabeled hGH for receptor binding and did not stimulate the hGH-receptor-dependent proliferation produced by full-length hGH.[6]
This supports a distinction between AOD9604 and intact hGH in the particular receptor-binding and proliferation systems used. It does not identify the direct molecular target responsible for the reported metabolic effects.
β3-Adrenergic-Receptor Knockout Mice
Another mouse study examined the relationship between AOD9604 and β3-adrenergic-receptor biology. Chronic exposure in obese wild-type mice was associated with lower body weight and body fat, increased lipolytic sensitivity, and increased adipose-tissue β3-adrenergic-receptor RNA expression.[7]
In β3-receptor knockout mice, the chronic changes in body weight and lipolysis observed in wild-type controls were not reproduced. However, acute AOD9604 exposure still increased energy expenditure and fat oxidation in the knockout animals.
The authors concluded that the lipolytic actions were not mediated by direct β3-receptor activation, although increased receptor expression could contribute to enhanced lipolytic sensitivity after chronic exposure.[7]
Evidence Concentration and Replication
The central metabolic findings derive largely from a small, historically connected research program and publications from approximately the same period. The presence of several papers should not be mistaken for broad independent replication across many laboratories.
Modern confirmation with blinded study design, contemporary peptide analytics, target-engagement methods, prespecified statistical plans, and independent reproduction remains limited.[5][6][7]
Human Evidence and Regulatory Context
Reported Human Trial Program
A 2013 publication summarized six randomized, double-blind, placebo-controlled trials conducted between 2001 and 2006, involving 893 participants in total. The program included single-dose intravenous studies, short oral studies, a 12-week oral study, and a 24-week oral study.
The publication reported no clinically meaningful increase in IGF-1, no deterioration in measured glucose-control endpoints, and no detected anti-AOD9604 antibodies in the samples selected for antibody testing. It characterized overall short-term tolerability as similar to placebo, although gastrointestinal events were more frequent at the highest oral dose in one short study.[8]
That publication is useful but should not be treated as an independent regulatory conclusion. The trials were funded by Metabolic Pharmaceuticals, and the paper disclosed financial and consulting relationships involving the sponsor and authors.
Much of the underlying trial information was presented as a retrospective summary rather than as complete, independently published clinical-study reports.[8]
Human Weight-Loss Efficacy Was Not Established
The largest obesity study is described with slightly different enrollment figures across summaries: the 2013 paper states that 534 individuals were enrolled and 502 were randomized, whereas FDA’s 2024 briefing describes a study enrolling 536 patients. These descriptions appear to concern the same pivotal development program and should not be combined as if they were separate trials.[8][2]
FDA concluded that the study did not show a statistically significant difference in weight loss at the 12-week primary endpoint compared with placebo, and that development for obesity was terminated after the study failed. FDA’s broader review found insufficient evidence to support effectiveness for obesity by any evaluated route of administration.[2]
Safety Conclusions Must Be Narrowly Framed
The human program provides limited evidence about short-term tolerability of the specific investigational materials and oral or intravenous regimens studied. It does not establish comprehensive long-term safety, safety of subcutaneous or transdermal administration, safety of independently manufactured research materials, safety of compounded products, or safety across different impurity and aggregation profiles.
FDA’s 2024 review identified insufficient long-term and route-specific safety information, no adequate human pharmacokinetic or pharmacodynamic characterization, and unresolved immunogenicity concerns related to peptide impurities, aggregation, formulation, concentration, manufacturing, and storage. FDA also discussed nonclinical signals suggestive of bone effects in rats, possible liver toxicity in cynomolgus monkeys, and equivocal findings in genotoxicity assays, while emphasizing limitations in exposure characterization and available study detail.[2]
FDA’s current compounding-risk page, updated April 22, 2026, lists AOD9604 among withdrawn bulk-substance nominations and states that compounded products may present immunogenicity and characterization risks, that safety information is limited, and that serious adverse events have been identified although causality is unclear.[9]
The defensible conclusion is not that “AOD9604 has no human data,” nor that “AOD9604 is proven safe.” The evidence supports a narrower statement: limited, sponsor-associated trials reported generally similar short-term tolerability to placebo for the studied materials and routes, while comprehensive long-term, route-specific, formulation-specific, and independently verified safety remains unestablished.
Molecular Target: What Is Known and What Remains Unresolved
The direct receptor or binding target responsible for AOD9604-associated lipid-metabolism findings has not been established in adipocytes or whole-body metabolic models. The available data argue against treating AOD9604 as a conventional hGH-receptor agonist or a classical direct β3-adrenergic-receptor agonist.[6][7]
In 2026, research involving LAT8881—a related therapeutic peptide developed from the AOD9604 sequence—identified lanthionine synthetase C-like protein 1 (LanCL1) as a binding and functional target in neuropathic-pain models. A photoaffinity probe enriched LanCL1, and siRNA knockdown blocked LAT8881 activity in the tested system.[10]
This is an important target-identification result for LAT8881 in neural pain models, but it does not establish LanCL1 as the mediator of AOD9604-associated adipocyte lipolysis, fat oxidation, or body-weight effects. Direct adipocyte target engagement, genetic loss-of-function, rescue experiments, and metabolic flux studies would be required before making that assignment.
Canonical Adipocyte Lipolysis Framework
Lipolysis is the regulated hydrolysis of triglycerides stored in intracellular lipid droplets. It is not controlled by a single enzyme.
- Adipose triglyceride lipase (ATGL) initiates hydrolysis of triglyceride to diacylglycerol.
- Hormone-sensitive lipase (HSL) has strong activity toward diacylglycerol and contributes substantially to stimulated lipolysis.
- Monoacylglycerol lipase (MGL) completes hydrolysis of monoacylglycerol to glycerol and a fatty acid.
ATGL, HSL, MGL, lipid-droplet proteins, coactivators, inhibitory proteins, intracellular localization, and substrate accessibility collectively determine the measured rate of lipid mobilization.[11]
cAMP–PKA Regulation
In canonical β-adrenergic stimulation, activation of a Gs-coupled receptor increases adenylyl-cyclase activity and intracellular cyclic AMP. Cyclic AMP activates protein kinase A, which regulates components of the lipid-droplet lipolysis system.
PKA-dependent phosphorylation contributes to HSL activation and relocation to the lipid-droplet surface. PKA also phosphorylates perilipin 1 and alters the organization of regulatory proteins around the droplet, increasing access of lipases to stored lipid.[12]
HSL residue numbering differs among species and isoforms. Site numbers reported in rat HSL should not be transferred automatically to human HSL without confirming sequence correspondence.
The cAMP–PKA–HSL–perilipin pathway is a general model of stimulated adipocyte lipolysis. It is not proof that AOD9604 directly activates adenylyl cyclase, raises cAMP, activates PKA, phosphorylates a specific HSL site, or phosphorylates perilipin.
A direct pathway claim would require matched AOD9604 experiments measuring, at minimum, several of the following:
- intracellular cAMP and PKA activity;
- species-appropriate HSL and perilipin phosphorylation;
- HSL and ATGL localization;
- glycerol and non-esterified fatty-acid release;
- receptor-selective pharmacology;
- genetic knockdown, knockout, and rescue;
- direct binding or target-engagement evidence.
Interpreting Glycerol and Fatty-Acid Release
Glycerol release is widely used as a marker of triglyceride hydrolysis. White adipocytes generally have relatively low glycerol-kinase activity, which limits glycerol reutilization and makes extracellular glycerol a useful experimental readout.
However, glycerol release should be measured over a validated linear interval and normalized appropriately. Interpretation depends on tissue mass or cell number, viability, medium composition, albumin concentration, sampling schedule, assay range, and the extent of substrate reutilization.[13]
Increased extracellular glycerol supports increased triglyceride hydrolysis under the tested conditions, but it does not independently identify:
- the upstream receptor or binding target;
- direct β3-receptor agonism;
- a complete cAMP–PKA mechanism;
- increased mitochondrial fatty-acid oxidation;
- long-term reduction in adipose mass;
- translation to another species or route of administration.
Non-esterified fatty acids released during lipolysis may remain extracellular, bind albumin, be taken up by nearby cells, undergo oxidation, or be re-esterified. A mismatch between glycerol and fatty-acid release can therefore reflect fatty-acid handling and re-esterification rather than an analytical error.
β3-Adrenergic Association and Species Differences
The β3-adrenergic receptor is an important regulator of rodent adipose metabolism. Its activation can promote cAMP signaling, lipolysis, and thermogenic responses.
The AOD9604 knockout-mouse study supports an association between chronic AOD9604 responses and β3-receptor expression or availability. It does not establish AOD9604 as a direct receptor ligand.
Persistence of acute energy-expenditure and fat-oxidation responses in knockout mice indicates that at least some short-term effects occurred without functional β3 receptors in that model.[7]
β3-adrenergic-receptor expression and regulation differ between rodents and humans. Comparative molecular work has identified species- and tissue-specific differences, and rodent adipose findings should not be assumed to predict human adipose biology directly.[14]
Pharmacological similarity to a known agonist, blockade by a nonselective antagonist, or convergence on a shared downstream signal would not independently prove direct binding. Strong target assignment generally requires orthogonal evidence, including direct binding, receptor-selective functional assays, genetic loss-of-function, rescue, and biophysical target engagement.
From Lipid Mobilization to Fatty-Acid Oxidation
Lipolysis and fatty-acid oxidation are related but distinct. Lipolysis releases fatty acids from triglycerides; oxidation requires transport, activation to fatty acyl-CoA, mitochondrial delivery where appropriate, and processing through β-oxidation.
Fatty-Acid Uptake
Extracellular fatty acids enter cells through a combination of diffusion and protein-facilitated transport. CD36, plasma-membrane fatty-acid-binding protein, and fatty-acid transport proteins can contribute, although their relative importance varies by tissue, nutritional state, hormonal conditions, and energy demand.[15]
The core AOD9604 studies did not establish direct regulation of CD36, FABPpm, or FATP expression or trafficking. These are potential downstream research endpoints, not confirmed AOD9604 targets.
Mitochondrial β-Oxidation
Long-chain fatty acids are activated to fatty acyl-CoA before mitochondrial oxidation. Carnitine palmitoyltransferase 1 generates acylcarnitine at the outer mitochondrial membrane, carnitine-acylcarnitine translocase transfers it across the inner membrane, and carnitine palmitoyltransferase 2 regenerates fatty acyl-CoA in the matrix.
The β-oxidation spiral then produces acetyl-CoA and reduced cofactors that support the citric-acid cycle and oxidative phosphorylation.[16]
CPT1 is regulated by metabolic conditions, including inhibition by malonyl-CoA. Increased fatty-acid availability therefore does not guarantee increased mitochondrial oxidation.
The obese-mouse study reported increased whole-body fat oxidation under its experimental conditions.[6] That result should not be expanded into a claim that AOD9604 directly activates CPT1, increases mitochondrial number, induces oxidative genes, or increases oxidation in every tissue or model.
Indirect Calorimetry and RER
Indirect calorimetry estimates energy expenditure and substrate use from oxygen consumption and carbon-dioxide production. Respiratory exchange ratio (RER) is calculated as carbon-dioxide production divided by oxygen consumption.
Under appropriate steady-state conditions, values closer to 0.7 indicate a greater relative contribution from fat oxidation, whereas values closer to 1.0 indicate a greater relative contribution from carbohydrate oxidation. RER is affected by feeding, activity, stress, circadian phase, acid-base status, and non-steady-state conditions.[17]
A lower RER indicates a shift in the relative substrate mixture under the measurement conditions. It does not independently prove increased total energy expenditure or long-term adipose loss.
Thermogenesis and UCP1 Remain Unresolved
Uncoupling protein 1 is an inner-mitochondrial-membrane protein with an established role in brown-adipose thermogenesis. Functional UCP1 permits proton conductance that reduces coupling between substrate oxidation and ATP production.
UCP1 messenger RNA does not necessarily predict protein abundance, and protein abundance alone does not prove thermogenic activity. Functional assessment may require mitochondrial respiration, proton-leak measurements, tissue temperature, oxygen consumption, adrenergic responsiveness, cold challenge, or whole-body energy-expenditure analysis.[18]
The principal AOD9604 studies did not establish a complete AOD9604-to-UCP1 pathway or demonstrate direct induction of UCP1 transcription, functional white-adipose browning, or UCP1-dependent thermogenesis. These remain proposed research questions rather than established effects.
Gene-Expression Claims Require Direct Evidence
Acute signaling, messenger-RNA adaptation, protein turnover, and tissue remodeling occur on different time scales. Phosphorylation and enzyme translocation may change within minutes, gene expression generally requires longer observation, and changes in adipose-depot mass may require substantially longer experiments.
Potential endpoints include:
- HSL, ATGL, MGL, perilipin 1, and ABHD5/CGI-58;
- CPT1 isoforms and mitochondrial fatty-acid transport;
- MCAD and other β-oxidation enzymes;
- PGC-1α and mitochondrial-biogenesis markers;
- UCP1 and other thermogenic markers;
- leptin, adiponectin, and inflammatory markers;
- β-adrenergic-receptor expression.
Among these categories, increased β3-adrenergic-receptor RNA expression was reported directly in the cited AOD9604 mouse study.[7]
The core literature does not provide a validated, comprehensive AOD9604-responsive gene-expression signature for HSL, ATGL, CPT1, MCAD, PGC-1α, UCP1, leptin, and adiponectin. Such genes should not be described as established AOD9604-regulated targets without study-specific evidence reporting model, tissue, exposure, platform, normalization, effect size, multiplicity control, and statistical analysis.
Tissue-Level Interpretation
Changes in body weight or adipose mass can result from altered food intake, water balance, lean mass, lipid synthesis, lipid mobilization, substrate oxidation, activity, thermogenesis, or tissue-specific adaptation.
A robust tissue-level study should ideally report:
- longitudinal body-weight curves;
- food intake and, where appropriate, pair-fed controls;
- fat mass and lean mass;
- individual adipose-depot and organ weights;
- adipocyte-size distributions;
- plasma glycerol and non-esterified fatty acids;
- glucose, insulin, and insulin-sensitivity measures;
- energy expenditure, RER, and locomotor activity;
- liver and muscle lipid accumulation;
- histology, molecular endpoints, and peptide exposure.
Adipose depots differ in vascularization, innervation, adipocyte size, receptor expression, inflammatory state, and metabolic function. Epididymal, gonadal, inguinal, retroperitoneal, mesenteric, and brown adipose tissues should be identified explicitly rather than grouped generically as “fat tissue.”
The available AOD9604 literature does not establish that one specific visceral depot universally responds more strongly than all subcutaneous depots.
Evidence-Strength Summary
| Claim | Evidence status | Appropriate interpretation |
|---|---|---|
| Reduced body-weight gain in selected obese rodent protocols | Directly reported | Supported only for the specific Zucker-rat and ob/ob-mouse experiments cited. |
| Increased adipose lipolytic activity or plasma glycerol in selected rodent models | Directly reported | Supports increased lipid mobilization under the tested conditions, not universal long-term fat loss. |
| Increased whole-body fat oxidation in obese mice | Directly reported | Does not prove direct activation of CPT1 or a tissue-specific mitochondrial target. |
| Direct activation of the hGH receptor | Not supported by the cited assay | AOD9604 did not compete with radiolabeled hGH or stimulate receptor-dependent proliferation in the tested system. |
| Direct β3-receptor agonism | Not established | Chronic effects were associated with receptor expression, but acute effects persisted in knockout mice. |
| Direct cAMP–PKA–HSL–perilipin activation | Biologically plausible but unproven | Requires direct compound-specific pathway measurements. |
| LanCL1 mediates adipocyte metabolic effects | Unresolved | LanCL1 was identified for LAT8881 in neuropathic-pain models, not for AOD9604 metabolic action. |
| Human weight-loss efficacy | Not established | The pivotal obesity study did not meet its prespecified primary efficacy endpoint. |
| Comprehensive human safety | Not established | Limited short-term trial tolerability does not establish long-term, route-specific, formulation-specific, or compounded-product safety. |
Analytical Identity and Certificate-of-Analysis Interpretation
Molecular identity data and a batch Certificate of Analysis answer different questions. A defensible COA should identify the exact chemical form and should not mix free-base identifiers with acetate specifications.
Depending on the intended research purpose, a peptide COA and supporting analytical package may include:
- batch or lot number and manufacturing date;
- exact sequence and disulfide configuration;
- free-base or salt identity and counterion result;
- mass-spectrometric identity data with charge-state interpretation;
- reversed-phase HPLC purity and method conditions;
- individual and total impurity limits;
- net peptide content or assay value;
- water content;
- residual solvents and process-related reagents;
- aggregate or oligomer assessment using a suitable orthogonal method;
- appearance, solubility, and storage conditions;
- microbial limits and bacterial endotoxin where relevant to the intended laboratory application;
- stability-indicating data and retest or expiry rationale.
What HPLC Area Percentage Does and Does Not Show
An HPLC area-percentage result estimates the relative chromatographic contribution of detected components under a particular method, wavelength, integration rule, and sample preparation. It does not independently establish:
- correct sequence or disulfide connectivity;
- net peptide mass fraction;
- water or counterion content;
- residual solvents or synthesis reagents;
- coeluting impurities or positional isomers;
- aggregates not adequately resolved by the method;
- sterility, endotoxin status, or suitability for administration.
A label such as “98%” or “99% HPLC purity” is therefore not equivalent to 98% or 99% net peptide by mass and is not, by itself, proof of biological safety or application suitability.
No Universal AOD9604 Release Specification Was Established
The publicly available evidence does not support a single universal industry specification for AOD9604. FDA reviewed submitted COAs that used limits such as no more than 1.0% for an individual impurity and no more than 2.0% for total impurities in one acetate-material context, but FDA did not endorse those values as a universal standard and still found the overall public characterization inadequate.[2]
Appropriate limits depend on the exact chemical form, synthesis process, impurity identities, intended analytical use, route and duration of exposure where applicable, stability profile, toxicological qualification, and method capability.
FDA’s AOD9604-Specific Characterization Concerns
FDA’s 2024 evaluation concluded that publicly available AOD9604 free-base and acetate information did not adequately characterize specific peptide impurities, aggregates, microbial quality, bacterial endotoxin for injectable use, particle size, or polymorphism for certain proposed dosage forms. FDA emphasized that disulfide reduction, dimer formation, and aggregate formation can complicate characterization and may affect immunogenicity risk.[2]
This does not mean that every batch necessarily contains unacceptable levels of these attributes. It means that a generic supplier COA with sequence, HPLC purity, and a mass result may be insufficient to demonstrate that a specific batch is comprehensively characterized.
Analytical-Method Validation
Relevant procedure-performance characteristics may include specificity or selectivity, accuracy, precision, detection limit, quantitation limit, linearity, range, and robustness, according to the purpose of the method. ICH Q2(R2) describes analytical-procedure validation principles, but it does not prescribe a universal AOD9604 purity, water, impurity, or counterion limit.[19]
A COA documents selected test results for one batch under specified methods. It does not demonstrate human efficacy, comprehensive safety, regulatory approval, sterility, or suitability for administration unless those questions have been addressed independently with appropriate validated evidence.
Research-Interpretation Checklist
Before drawing conclusions from an AOD9604 experiment, confirm:
- the exact sequence and Cys7–Cys14 disulfide configuration;
- whether the material is free base, acetate, another salt, or an incompletely defined form;
- whether the tested compound is AOD9604, hGH 177–191, AOD9401, LAT8881, or another related peptide;
- the counterion, water content, net peptide content, impurity profile, and aggregate status;
- the species, strain, sex, age, metabolic phenotype, and sample size;
- the exact cell type, adipose depot, or tissue;
- the exposure schedule, formulation, route, and verified peptide stability;
- vehicle, positive, and negative controls;
- randomization, blinding, exclusion criteria, and prespecified statistical analysis;
- cell viability or tissue integrity;
- linear assay intervals for glycerol and fatty-acid release;
- whether molecular endpoints were measured directly or inferred from general biology;
- whether findings were independently replicated;
- whether conclusions remain limited to the experimental system and route used.
Balanced Conclusion
The most defensible interpretation is that AOD9604 produced measurable lipid-metabolism-related effects in several defined obese rodent models. These included reduced body-weight gain, increased adipose lipolytic activity or plasma glycerol, increased whole-body fat oxidation, and a complex association with β3-adrenergic-receptor expression.
The published evidence does not establish a complete receptor-to-effector mechanism for AOD9604 in adipocytes. Direct hGH-receptor activation was not supported in the cited engineered-cell assay, direct β3-receptor agonism was not demonstrated, and the canonical cAMP–PKA–HSL pathway remains an interpretive framework rather than a fully measured compound-specific pathway.
LanCL1 is an important target identified for the related peptide LAT8881 in neuropathic-pain models, but its relevance to AOD9604 metabolic effects is unresolved.
Human trials provide limited short-term tolerability information for specific investigational materials and oral or intravenous regimens, but they did not establish clinically reliable weight-loss efficacy. They also do not resolve long-term, subcutaneous, transdermal, formulation-specific, compounded-product, or impurity-dependent safety.
FDA’s AOD9604-specific review identified substantial gaps in effectiveness, pharmacokinetics, physicochemical characterization, impurity and aggregate control, immunogenicity assessment, and route-specific safety.
Accordingly, rodent metabolic findings should not be presented as proof of human efficacy, and a batch HPLC value or matching mass should not be presented as proof of comprehensive identity, purity, sterility, safety, or regulatory suitability.
References
- PubChem. AOD9604, CID 71300630.
- U.S. Food and Drug Administration. Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 Free Base and AOD-9604 Acetate) for Inclusion on the 503A Bulks List. Pharmacy Compounding Advisory Committee briefing document, 2024.
- Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177–191 of human growth hormone.
- Ng FM et al. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats.
- Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.
- Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
- Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knockout mice.
- Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 2013;3(1–2):7–15.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of April 22, 2026.
- Spanswick DC et al. Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain. PAIN. 2026.
- Duncan RE et al. Regulation of lipolysis in adipocytes.
- Sztalryd C, Brasaemle DL. The perilipin family of lipid-droplet proteins: gatekeepers of intracellular lipolysis.
- Bridge-Comer PE, Reilly SM. Measuring the rate of lipolysis in ex vivo murine adipose tissue and primary preadipocytes differentiated in vitro.
- Granneman JG et al. Analysis of human and rodent β3-adrenergic-receptor messenger ribonucleic acids.
- van Hall G. The physiological regulation of skeletal-muscle fatty-acid supply and oxidation.
- Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty-acid β-oxidation.
- Gupta RD et al. Indirect calorimetry: from bench to bedside.
- Harms M, Seale P. Brown adipose tissue biology: molecular control of brown-fat development and energy homeostasis.
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. 2023.
Research-Use Disclaimer
This article is provided for educational discussion of published evidence and analytical-quality principles. It is not medical, pharmaceutical, veterinary, compounding, or treatment guidance.
It does not establish the safety, efficacy, identity, sterility, or suitability of any commercial or research batch. Decisions involving human or animal health must be made within applicable law and by appropriately qualified professionals using approved products and validated evidence.
Evidence and regulatory context reviewed through July 2026.